Computer aided drug discovery of highly ligand efficient, low molecular weight imidazopyridine analogs as FLT3 inhibitors

European Journal of Medicinal Chemistry
Brendan FrettHong-yu Li

Abstract

The FLT3 kinase represents an attractive target to effectively treat AML. Unfortunately, no FLT3 targeted therapeutic is currently approved. In line with our continued interests in treating kinase related disease for anti-FLT3 mutant activity, we utilized pioneering synthetic methodology in combination with computer aided drug discovery and identified low molecular weight, highly ligand efficient, FLT3 kinase inhibitors. Compounds were analyzed for biochemical inhibition, their ability to selectively inhibit cell proliferation, for FLT3 mutant activity, and preliminary aqueous solubility. Validated hits were discovered that can serve as starting platforms for lead candidates.

References

Jan 1, 1992·Drug Metabolism Reviews·A DurandP L Morselli
Oct 29, 2000·The Journal of Organic Chemistry·C EnguehardA Gueiffier
Feb 5, 2004·Molecular Cell·James GriffithKumkum Saxena
Jan 6, 2007·Leukemia·D AuclairS M Wilhelm
Aug 11, 2007·Nature Reviews. Drug Discovery·Sandrine FaivreEric Raymond
Mar 7, 2012·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Nadine AndraeChristian Mawrin
Apr 25, 2013·International Journal of Hematology·Michael R Grunwald, Mark J Levis
May 23, 2013·British Journal of Haematology·Neil P ShahJorge E Cortes
Sep 5, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jorge E CortesMark Levis
Sep 26, 2013·Bioorganic & Medicinal Chemistry Letters·James R BurgesonDongcheng Dai
Feb 1, 2014·Nature Reviews. Drug Discovery·Andrew L HopkinsCharles H Reynolds
Mar 14, 2014·Proceedings of the National Academy of Sciences of the United States of America·Catherine Choy SmithNeil P Shah
Sep 19, 2014·European Journal of Medicinal Chemistry·Brendan FrettHong-yu Li

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.